Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors
| العنوان: | Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors |
|---|---|
| المؤلفون: | Phyo T. Htoo, Virginia Pate, M. Alison Marquis, Til Stürmer, Mugdha Gokhale, John B. Buse |
| المصدر: | European Journal of Clinical Pharmacology. 72:1013-1023 |
| بيانات النشر: | Springer Science and Business Media LLC, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Male, Oncology, endocrine system, medicine.medical_specialty, Colorectal cancer, Incretin, 030209 endocrinology & metabolism, Pharmacology, Mouse model of colorectal and intestinal cancer, Glucagon-Like Peptide-1 Receptor, Article, 03 medical and health sciences, 0302 clinical medicine, Diabetes mellitus, Internal medicine, Diabetes Mellitus, medicine, Humans, Hypoglycemic Agents, Pharmacology (medical), 030212 general & internal medicine, Dipeptidyl peptidase-4, Aged, Aged, 80 and over, business.industry, Incidence, digestive, oral, and skin physiology, Hazard ratio, Cancer, General Medicine, medicine.disease, Glucagon-like peptide-1, Sulfonylurea Compounds, Female, Thiazolidinediones, Colorectal Neoplasms, business, hormones, hormone substitutes, and hormone antagonists |
| الوصف: | Incretin-based antihyperglycemic therapies increase intestinal mucosal expansion and polyp growth in mouse models. We aimed to evaluate the effect of dipeptidyl peptidase-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonists (GLP-1ra) initiation on colorectal cancer incidence. We conducted a cohort study on US Medicare beneficiaries over age 66 from 2007 to 2013 without prevalent cancer. We identified three active-comparator and new-user cohorts: DPP-4i versus thiazolidinediones (TZD), DPP-4i versus sulphonylureas (SU), and GLP-1ra versus long acting insulin (LAI). Follow-up started from 6 months post-second prescription and ended 6 months after stopping (primary as-treated analysis). We estimated hazard ratios (HR) and 95 % confidence intervals (CI) for incident colorectal cancer adjusting for measured confounders using propensity score weighting. The median duration of treatment ranged 0.7–0.9 years among DPP-4i cohorts. Based on 104 events among 39,334 DPP-4i and 63 events among 25,786 TZD initiators, there was no association between DPP-4i initiation and colorectal cancer (adjusted HR = 1.17 (CI 0.88, 1.71)). There were 73 events among 27,047 DPP-4i and 266 events among 76,012 SU initiators with the adjusted HR 0.98 (CI 0.74, 1.30). We identified 5600 GLP-1ra and 54,767 LAI initiators and the median duration of treatment was 0.8 and 1.2 years, respectively. The adjusted HR was 0.82 (CI 0.42, 1.58) based on |
| تدمد: | 1432-1041 0031-6970 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7006f8c502f31a1db8e3e7313aeb6ceeTest https://doi.org/10.1007/s00228-016-2068-3Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....7006f8c502f31a1db8e3e7313aeb6cee |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14321041 00316970 |
|---|